- BioMark Diagnostics (CSE:BUX) presented its latest leading-edge research in the field of lung cancer.
- The Vancouver-based liquid biopsy company took the stage at the 2023 American Society of Clinical Oncology (ASCO) annual meeting in Chicago
- The objectives of the study were to validate whether BioMark’s panel of metabolomic biomarkers improved early lung cancer detection in over 800 plasma samples from patients that underwent lung cancer resection, and to understand the potential role and intersection between lung cancer and other lung diseases
- BioMark Diagnostics Inc. (BUX) opened trading at $0.32 per share
BioMark Diagnostics (CSE:BUX) presented its latest leading-edge research in the field of lung cancer.
The Vancouver-based liquid biopsy company took the stage at the 2023 American Society of Clinical Oncology (ASCO) annual meeting in Chicago.
The seminar entitled “Large retrospective validation study of metabolomic biomarkers for resectable lung cancer detection and risk assessment”, was presented by senior author, Dr Andrew Maksymiuk. The objectives of the study were to validate whether BioMark’s panel of metabolomic biomarkers improved early lung cancer detection in over 800 plasma samples from patients that underwent lung cancer resection, and to understand the potential role and intersection between lung cancer and other lung diseases.
The company’s Chief Strategy Officer and General Manager of BioMark Diagnostic Solutions, Jean-François Haince, explained that the blood-based metabolites panel validated on BioMark’s current retrospective study yielded sensitivity of 91 per cent and specificity over 78 per cent for all lung cancer detection.
“Furthermore, what is also very promising is the ability of the assay to yield over 92 per cent sensitivity for early stage (I and II) lung cancer. This metabolomic panel assay demonstrates potential diagnostic applications and clinical utility for patient selection that require further follow-up and confirmation using LDCT or other lung imaging modalities.”
Rashid Bux, Chief Executive of BioMark, added that the team is focused on the commercialization of this important molecular assay that addresses a significant need in improving cancer management related in early lung cancer detection.
“BioMark is poised to take it’s blood-based metabolomic biomarker panel to the next level and bring new hope to people at high risk of developing lung cancer.”
BioMark is a liquid biopsy company developing a molecular diagnostics technology platform that uses large-scale cell studies (metabolomics) and machine learning algorithms for new cancer diagnostics and to improve cancer prognosis. Its technology can also be used for measuring response to treatment. BioMark recently announced that the U.S. Patent and Trademark Office granted a patent with claims covering its lung cancer liquid biopsy assay. Click here to read more.
BioMark Diagnostics Inc. (BUX) opened trading at $0.32 per share.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.
